Get the Stockscreener App
2.34
7.83%
0.17
Gossamer Bio Inc stock is traded at $2.34, with a volume of 4.89M.
It is up +7.83% in the last 24 hours and up +36.05% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
See More
Previous Close:
$2.17
Open:
$2.17
24h Volume:
4.89M
Relative Volume:
2.00
Market Cap:
$532.07M
Revenue:
-
Net Income/Loss:
$-179.82M
P/E Ratio:
-1.7594
EPS:
-1.33
Net Cash Flow:
$-159.16M
1W Performance:
+19.39%
1M Performance:
+36.05%
6M Performance:
+67.14%
1Y Performance:
+162.60%
1-Day Range:
$2.145
$2.35
1-Week Range:
$1.88
$2.35
52-Week Range:
$0.6617
$2.35
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 684-1300
Address
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
2.34 | 452.49M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
Quant Strategy Flags Gossamer Bio Inc. for EntryWeekly Market Summary & Community Verified Trade Signals - newsyoung.net
Visual trend scoring systems applied to Gossamer Bio Inc.Market Performance Summary & AI Powered Market Trend Analysis - Newser
H.C. Wainwright and Leerink Partners Reiterate ‘Buy’ Ratings on Gossamer Bio, Inc. (GOSS) - MSN
H.C. Wainwright reiterates Buy rating on Gossamer Bio stock at $10 - Investing.com
Will Gossamer Bio Inc. continue its uptrendGold Moves & Smart Swing Trading Techniques - Newser
Automated trading signals detected on Gossamer Bio Inc.2025 Stock Rankings & Real-Time Chart Breakout Alerts - Newser
What machine learning models say about Gossamer Bio Inc.Portfolio Return Report & AI Enhanced Execution Alerts - Newser
Chartists Watching For Breakout in Gossamer Bio Inc.2025 Key Lessons & Fast Gain Swing Alerts - beatles.ru
Why Gossamer Bio Inc. is moving todayJuly 2025 Intraday Action & Daily Chart Pattern Signals - Newser
What institutional flow reveals about Gossamer Bio Inc.Weekly Trade Summary & Accurate Entry and Exit Point Alerts - Newser
Multi asset correlation models including Gossamer Bio Inc.Weekly Stock Report & Safe Capital Growth Trade Ideas - Newser
What is the earnings history of Gossamer Bio Inc.Global Markets & Fast Gaining Stock Reports - classian.co.kr
Gossamer Bio Revenue Estimates Surge Higher Amid Analyst Upgrades - AInvest
Analysts' Revenue Estimates For Gossamer Bio, Inc. (NASDAQ:GOSS) Are Surging Higher - Yahoo Finance
Pulmonary Hypertension associated with Interstitial Lung Disease Market to Witness Upsurge in Growth During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Gossamer Bio Inc.’s Beta Climbs After Market VolatilityJuly 2025 Summary & High Yield Stock Recommendations - classian.co.kr
Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates - MSN
Gossamer Bio shares rise 1.52% after-hours following XOMA Royalty's acquisitions and pipeline advancements. - AInvest
Gossamer Bio Reports Q2 2025 Financial Results - MSN
Analyzing recovery setups for Gossamer Bio Inc. investorsAI-Powered Stock Trend Movement Analysis - Newser
Q3 EPS Estimates for Gossamer Bio Increased by HC Wainwright - Defense World
Wedbush Has Optimistic Outlook of Gossamer Bio Q3 Earnings - Defense World
Will Gossamer Bio Inc. see short term momentumStock Portfolio Risk and Return Analysis - Newser
Is Gossamer Bio Inc. stock poised for growthGrowth Watchlist for Long Term Positioning - Newser
Institutional investors in Gossamer Bio, Inc. (NASDAQ:GOSS) see US$54m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Is Gossamer Bio Inc. trending in predictive chart modelsOversold Stock Bounce Playbook Generator - Newser
What makes Gossamer Bio Inc. stock price move sharplyReal-Time Investment Signal Forecast with AI - Newser
Gossamer Bio (NASDAQ:GOSS) Stock Rating Lowered by Wall Street Zen - Defense World
Real time scanner hits for Gossamer Bio Inc. explainedMarket Timing Strategy with Technical Filters - Newser
Q3 EPS Estimates for Gossamer Bio Lowered by Leerink Partnrs - Defense World
H.C. Wainwright Maintains Gossamer Bio(GOSS.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 7, 2025 - BioSpace
Gossamer Bio earnings beat by $0.01, revenue topped estimates - Investing.com Australia
Gossamer Bio Reports Q2 2025 Financials, Announces PROSERA Phase 3 Topline Results Expected in February 2026, and First Site Activations for Registrational Phase 3 SERANATA Study in PH-ILD Expected in Q4 2025. - AInvest
Gossamer Bio 2025 Q2 Earnings Sharp Net Loss Amid Revenue Drop - AInvest
Gossamer Bio 2025 Q2 Earnings Sharp Net Income Decline of 177.7% - AInvest
Gossamer Bio shares fall 7.41% premarket despite beating earnings expectations. - AInvest
Gossamer Bio Inc. Exceeds Q2 Expectations Despite LossNews and Statistics - IndexBox
Gossamer Bio: Q2 Earnings Snapshot - New Haven Register
Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
How Gossamer Bio Inc. stock performs during market volatilityBuy and Exit Strategy Based on Momentum - Newser
Gossamer Bio shares rise 1.39% after-hours despite Q2 revenue drop of 88%. - AInvest
GOSS Achieves Strong Q2 Revenue and Prepares for Commercial Expa - GuruFocus
Gossamer Bio Reports Q2 Revenue Drop of 88% - AInvest
Gossamer Bio Q2 revenue drops 88% - MarketScreener
Gossamer Bio's 390-Patient PAH Trial Nears Crucial February Readout, $213M Cash Runway - Stock Titan
Will Gossamer Bio Inc. price bounce be sustainableFree Smart Trade Plans With Risk Protection - Newser
Can Gossamer Bio Inc. rally from current levelsStrategy Builder for Growth Focused Traders - Newser
Why is Gossamer Bio Inc. stock attracting strong analyst attentionExponentially increasing returns - Jammu Links News
Custom strategy builders for tracking Gossamer Bio Inc.Market Liquidity and Price Flow Analysis - Newser
Published on: 2025-08-04 06:30:01 - beatles.ru
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):